Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group.

Veal GJ, Cole M, Errington J, Pearson AD, Foot AB, Whyman G, Boddy AV; UKCCSG Pharmacology Working Group..

Br J Cancer. 2007 Feb 12;96(3):424-31.

2.

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson AD, Boddy AV.

Clin Cancer Res. 2013 Jan 15;19(2):469-79. doi: 10.1158/1078-0432.CCR-12-2225.

3.

Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma.

Veal G, Rowbotham S, Boddy A.

Therapie. 2007 Mar-Apr;62(2):91-3.

PMID:
17582307
4.

Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation.

Khan AA, Villablanca JG, Reynolds CP, Avramis VI.

Cancer Chemother Pharmacol. 1996;39(1-2):34-41.

PMID:
8995497
5.

Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.

Gota V, Chinnaswamy G, Vora T, Rath S, Yadav A, Gurjar M, Veal G, Kurkure P.

Cancer Chemother Pharmacol. 2016 Oct;78(4):763-8. doi: 10.1007/s00280-016-3126-3.

PMID:
27541143
6.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP.

N Engl J Med. 1999 Oct 14;341(16):1165-73.

7.

Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.

Matthay KK.

Clin Cancer Res. 2013 Jan 15;19(2):311-3. doi: 10.1158/1078-0432.CCR-12-3313.

9.

13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group.

Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL, Hammond GD.

Med Pediatr Oncol. 1992;20(4):307-11.

PMID:
1608352
10.

Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma.

Marabelle A, Sapin V, Rousseau R, Periquet B, Demeocq F, Kanold J.

Pediatr Blood Cancer. 2009 Feb;52(2):280-3. doi: 10.1002/pbc.21768.

PMID:
18839433
11.

Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.

Sonawane P, Cho HE, Tagde A, Verlekar D, Yu AL, Reynolds CP, Kang MH.

Br J Pharmacol. 2014 Dec;171(23):5330-44. doi: 10.1111/bph.12846.

12.
13.

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.

Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP.

J Clin Oncol. 1995 Apr;13(4):894-901.

PMID:
7707116
14.
16.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.

Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1.

PMID:
23314734
17.

Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children.

Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE.

Blood. 1992 Jun 1;79(11):2849-54.

18.

Clinical pharmacokinetics of carboplatin in children.

Riccardi R, Riccardi A, Lasorella A, Di Rocco C, Carelli G, Tornesello A, Servidei T, Iavarone A, Mastrangelo R.

Cancer Chemother Pharmacol. 1994;33(6):477-83.

PMID:
8137457
19.

The metabolism and pharmacokinetics of isotretinoin in patients with acne and rosacea are not influenced by ethanol.

Grønhøj Larsen F, Jakobsen P, Grønhøj Larsen C, Heidenheim M, Held E, Nielsen-Kudsk F.

Br J Dermatol. 2009 Sep;161(3):664-70. doi: 10.1111/j.1365-2133.2009.09241.x.

PMID:
19563582
20.

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

Children's Oncology Group (CCG 09709)., Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP.

J Clin Oncol. 2006 Jul 20;24(21):3423-30. Erratum in: J Clin Oncol. 2006 Sep 1;24(25):4223. Reynolds, Patrick C [corrected to Reynolds, C Patrick].

PMID:
16849757
Items per page

Supplemental Content

Support Center